Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

KD 5170

Known as: KD-5170, KD5170 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Combination therapy is often an effective strategy to treat cancer. In this study, we examined the growth-inhibitory effects of… Expand
Is this relevant?
2017
2017
Histone deacetylase inhibitors (HDACi) are being investigated for the control of various human parasites. Here we investigate… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 4
Is this relevant?
2008
2008
Histone deacetylase inhibitors have emerged as promising anticancer drugs. Using an unbiased ultrahigh throughput screening… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2008
2008
Histone deacetylase (HDAC) inhibitors have garnered significant attention as cancer drugs. These therapeutic agents have recently… Expand
  • figure 1
  • table 1
  • table 1
  • table 2
  • figure 2
Is this relevant?
2008
2008
We report the identification of KD5170, a potent mercaptoketone-based Class I and II-histone deacetylase inhibitor that… Expand
Is this relevant?
2008
2008
Histone deacetylase (HDAC) inhibitors have garnered significant attention as cancer drugs. These therapeutic agents have recently… Expand
  • figure 1
  • table 1
  • table 1
  • table 2
  • figure 2
Is this relevant?
2006
2006
Multiple Myeloma (MM) is characterized by the malignant proliferation of plasma cells and high osteoclast (OCL) activity… Expand
Is this relevant?